当前位置: 首页 >> 检索结果
6261. Impact of Intravascular Ultrasound-Guided Optimal Stent Expansion on 3-Year Hard Clinical Outcomes.
作者: Yong-Joon Lee.;Jun-Jie Zhang.;Gary S Mintz.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Byeong-Keuk Kim.;Young-Guk Ko.;Donghoon Choi.;Yangsoo Jang.;Jing Kan.;Tao Pan.;Xiaofei Gao.;Zhen Ge.;Shao-Liang Chen.;Myeong-Ki Hong.
来源: Circ Cardiovasc Interv. 2021年14卷10期e011124页
[Figure: see text].
6262. Impact of Diastolic Vessel Restriction on Quality of Life in Symptomatic Myocardial Bridging Patients Treated With Surgical Unroofing: Preoperative Assessments With Intravascular Ultrasound and Coronary Computed Tomography Angiography.
作者: Takehiro Hashikata.;Yasuhiro Honda.;Hanjay Wang.;Vedant S Pargaonkar.;Takeshi Nishi.;M Brooke Hollak.;Ian S Rogers.;Koen Nieman.;Paul G Yock.;Peter J Fitzgerald.;Ingela Schnittger.;Jack H Boyd.;Jennifer A Tremmel.
来源: Circ Cardiovasc Interv. 2021年14卷10期e011062页
[Figure: see text].
6264. Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement in Severe Mitral Annular Calcification: An Analysis of the Transcatheter Mitral Valve Replacement in Mitral Annular Calcification Global Registry.
作者: Abdallah El Sabbagh.;Mohammed Al-Hijji.;Dee Dee Wang.;Mackram Eleid.;Marina Urena.;Dominique Himbert.;Tarun Chakravarty.;David Holzhey.;Ashish Pershad.;H Kenith Fang.;Mohammed Nejjari.;Firas Zahr.;Danny Dvir.;Muhammad Rizwan Sardar.;Asim N Cheema.;Sami Alnasser.;Vijay Iyer.;Georges Kaddissi.;John Webb.;Raj Makkar.;Alec Vahanian.;William O'Neill.;Charanjit Rihal.;Mayra Guerrero.
来源: Circ Cardiovasc Interv. 2021年14卷10期e010854页
[Figure: see text].
6266. Regional and Temporal Variation of Ventricular and Conduction Tissue Activity During Ventricular Fibrillation in Canines.
作者: Nicholas Y Tan.;Georgios Christopoulos.;Thomas P Ladas.;Zhi Jiang.;Alan M Sugrue.;Jason A Tri.;Elena G Tolkacheva.;Freddy Del-Carpio Munoz.;Christopher J McLeod.;Samuel J Asirvatham.;Christopher V DeSimone.
来源: Circ Arrhythm Electrophysiol. 2021年14卷10期e010281页
[Figure: see text].
6267. Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial.
作者: Huilei Xu.;Claudia Hon.;Sergio Kaiser.;Pablo Serrano-Fernandez.;Nicole Hartmann.;Denise P Yates.;Margaret Healey.;Arkady I Gusev.;Jason M Laramie.;Scott Kennedy.;Philippe Marc.;Paul M Ridker.;Ma'en Obeidat.;Michael T Beste.;Eric C Svensson.;Aviv Madar.
来源: Circ Genom Precis Med. 2021年14卷6期e003440页 6270. Rat Model of Heart Failure With Preserved Ejection Fraction: Changes in Contractile Proteins Regulating Ca2+ Cycling and Vascular Reactivity.
作者: Young Soo Han.;Grace M Arteaga.;Korosh Sharain.;Gary C Sieck.;Frank V Brozovich.
来源: Circulation. 2021年144卷16期1355-1358页 6271. Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease.
作者: Paolo Calabrò.;Felice Gragnano.;Giampaolo Niccoli.;Rossella Marcucci.;Marco Zimarino.;Carmen Spaccarotella.;Giulia Renda.;Giuseppe Patti.;Giuseppe Andò.;Elisabetta Moscarella.;Massimo Mancone.;Arturo Cesaro.;Gennaro Giustino.;Raffaele De Caterina.;Roxana Mehran.;Davide Capodanno.;Marco Valgimigli.;Stephan Windecker.;George D Dangas.;Ciro Indolfi.;Dominick J Angiolillo.
来源: Circulation. 2021年144卷16期1323-1343页
Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.
6272. Letter by Wu et al Regarding Article, "Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779".6273. Social Vulnerability and Premature Cardiovascular Mortality Among US Counties, 2014 to 2018.
作者: Safi U Khan.;Zulqarnain Javed.;Ahmad N Lone.;Sourbha S Dani.;Zahir Amin.;Sadeer G Al-Kindi.;Salim S Virani.;Garima Sharma.;Ron Blankstein.;Michael J Blaha.;Miguel Cainzos-Achirica.;Khurram Nasir.
来源: Circulation. 2021年144卷16期1272-1279页
Substantial differences exist between United States counties with regards to premature (<65 years of age) cardiovascular disease (CVD) mortality. Whether underlying social vulnerabilities of counties influence premature CVD mortality is uncertain.
6278. Response by He et al to Letter Regarding Article, "Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779".6279. First Bicaval Valve Implantation in a Heart Transplant Patient to Treat Severe Symptomatic Tricuspid Regurgitation.
作者: Rafael Romaguera.;Gerard Roura.;Alex Ruiz-Majoral.;Ángel Sánchez-Recalde.;Carles Díez-López.;Daniel Fontes-Caramé.;Josep Comin-Colet.;Joan A Gómez-Hospital.
来源: Circ Heart Fail. 2021年14卷11期e008491页 6280. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
作者: Maria Cecilia Bahit.;Ralph L Sacco.;J Donald Easton.;Juliane Meyerhoff.;Lisa Cronin.;Eva Kleine.;Claudia Grauer.;Martina Brueckmann.;Hans-Christoph Diener.;Renato D Lopes.;Michael Brainin.;Phillippe Lyrer.;Rolf Wachter.;Tomas Segura.;Christopher B Granger.; .
来源: Circulation. 2021年144卷22期1738-1746页
A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation. Better understanding of the risk for development of AF is critical to implement optimal monitoring strategies with the goal of preventing recurrent stroke attributable to underlying AF. The RE-SPECT ESUS trial (Randomized, Double-Blind Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) provides an opportunity to assess predictors for developing AF and associated recurrent stroke.
|